Matthias Salathe, MD
Pulmonary Disease · Miami, FLNPI 1760414767
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (56.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Bristol Myers Squibb accounts for 99.1% of it on its own, with 2 other manufacturers making up the rest.
Across 5 payments — averaging $1061.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$5K
- Chiesi USA, Inc.$24
- Insmed, Inc.$21
Across 12 payments — averaging $4747.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$53K
- AbbVie$3K
- PTC Therapeutics, Inc.$355
- Novartis$33
What the payments were for
- Consulting fees$2,00038%
- Travel & lodging$3,00057%
- Food & beverage$2855%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 3 | $5,264 |
| Chiesi USA, Inc. | 1 | $24 |
| Insmed, Inc. | 1 | $21 |
How this compares
$5,309 in reported general payments places this provider in the 60th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 49 | $1,265,463 |
| CaystonAztreonam Lysine | 11 | $130,332 |
| CreonLipase/Protease/Amylase | 19 | $70,159 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Miami
- Javier Perez FernandezMiami$496K
- Raul ValorMiami$232K
- Shirin ShafazandMiami$193K
- Michael HernandezMiami$153K
- Ignacio CendanMiami$140K
- Andres SosaMiami$91K
- Jaime AvecillasMiami$70K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.